Stoke Therapeutics, Inc. announced that veteran biotech executive Arthur Tzianabos, who has extensive experience in the development and commercialization of rare disease treatments, will join the company’s board of directors. Dr. Tzianabos, the CEO and president of Homology Medicines, joins the board as Stoke is advancing toward the clinic with a pipeline of oligonucleotide therapies that aim to address the root cause of severe genetic diseases, starting with Dravet Syndrome. He previously served as president and CSO of OvaScience, where he translated early science into treatments for fertility patients.